How your com­pa­ny can fund the work at End­points News — and give your em­ploy­ees com­plete ac­cess to our con­tent

Last sum­mer we launched a prod­uct — En­ter­prise — that is es­sen­tial to the fu­ture of End­points News. Cor­po­rate cus­tomers can now di­rect­ly sup­port our fu­ture de­vel­op­ment through paid sub­scrip­tions, and get a list of ex­tra ben­e­fits and con­tent. If you’d like to sup­port the work, please con­sid­er do­ing so to­day. (We al­so have a prod­uct for in­di­vid­u­als called In­sid­er, which you can read about here.)

The news is this: We want to hit our sub­scrip­tion rev­enue goals now so we can ex­pand the team, bring­ing you even bet­ter re­port­ing soon­er rather than lat­er.  It’s just $1,000/year for your en­tire com­pa­ny no mat­ter the size — and you can see one of the ben­e­fits be­low. Every em­ploy­ee who sub­scribes to End­points News will be­gin to see this new spe­cial email head­er that demon­strates your com­pa­ny’s sup­port.

Spe­cial head­er em­ploy­ees would see with an En­ter­prise sub­scrip­tion


This isn’t a plea for do­na­tions. With a paid sub­scrip­tion, we’re pro­vid­ing you val­ue and new tools (more on that be­low) and in ex­change we’re charg­ing a price.

To do in­de­pen­dent jour­nal­ism root­ed in the style John and I have set out since we launched — 2 years, 3,700 ar­ti­cles and 500 dai­ly newslet­ters ago — here’s one ab­solute truth: Read­ers must di­rect­ly sup­port the busi­ness mod­el. And now your com­pa­ny can.

Give your em­ploy­ees full ac­cess to end­points news

Let’s say your com­pa­ny has 2,000 em­ploy­ees. Per­haps 500 of them vis­it our web­site and 50 of them are free email sub­scribers. For just $1,000/year, you can in­stant­ly up­grade all 50 to En­ter­prise — and then as long as your sub­scrip­tion is cur­rent, we’ll au­to­mat­i­cal­ly flag all new email sub­scribers from your cor­po­rate do­main and grant them full ac­cess to your firm’s En­ter­prise li­cense.

All of your em­ploy­ees who sub­scribe to End­points News will see the spe­cial head­er in their newslet­ter, re­mind­ing them of your com­pa­ny’s sup­port of in­de­pen­dent jour­nal­ism. We’ll send them all pre­mi­um End­points con­tent which is ex­clu­sive to paid sub­scribers on­ly. And there’s more. Your em­ploy­ees al­so get:

  • Print-to-PDF: The PDF but­ton above all our news ar­ti­cles will now work.
  • Cut-and-paste rights: Share our work legal­ly in full, with­out the URL, in­ter­nal­ly or with part­ners, in any dig­i­tal medi­um. A huge li­brary of news con­tent at their fin­ger­tips. With­out a sub­scrip­tion, just a fair-use, lim­it­ed amount is per­mis­si­ble.
  • Reprint rights: Go ahead and print our ma­te­r­i­al for busi­ness use, they’d have our full per­mis­sion.

And now:

    • Two Pre­mi­um Job List­ings: At End­points Ca­reers, we of­fer a way for cor­po­rate sub­scribers to get their open po­si­tions in front of our en­tire sub­scriber base. We’re of­fer­ing two free Pre­mi­um List­ings per year to each cor­po­rate cus­tomer. That is an $1,800 cost by it­self, which alone ex­ceeds the cost of a one year sub­scrip­tion.

Pay­wall ac­cess

Once you sub­scribe, here’s just a sam­ple of the con­tent every­one at your com­pa­ny will have ac­cess to:

Where the mon­ey is: Top 100 VCs in­vest­ing in US biotechs dur­ing 2017


What you need to know about this record-set­ting biotech IPO burst as 5 more crash the par­ty look­ing for $547M


The good, the bad and the ug­ly for the top 15 spenders in the glob­al drug R&D busi­ness: 2018


Where does the sci­ence come from? The top 20 NIH-fund­ed in­sti­tu­tions in 2017


What are the top 10 cor­po­rate VCs in bio­phar­ma to­day? And what do they want to fund — or steer clear of?


The top 20 rare dis­ease spe­cial­ists spot­light key biotech trends be­hind the boom

… and much more to come


Now is the time to sup­port the work

To the hun­dreds of amaz­ing com­pa­nies and in­di­vid­u­als who’ve al­ready signed up, thank you — what we do isn’t pos­si­ble with­out you.

If you’ve been think­ing about it but have put it off, we to­tal­ly get it. But we need your help this month if we’re to hit the lofty to­tals that’ll al­low us to hire a top-class team and build new prod­ucts while main­tain­ing our in­de­pen­dence.

Get End­points En­ter­prise

We’ve de­signed a re­al­ly easy form that takes a cou­ple min­utes to fill out, and re­quires a cred­it card pay­ment at the end. With­in 24 hours, usu­al­ly much soon­er, you’ll get an email with a full PDF li­cense. You can see the en­tire terms and con­di­tions here. All of your em­ploy­ees can start en­joy­ing the ben­e­fits of a sub­scrip­tion im­me­di­ate­ly.

Need help? Now many com­pa­nies have com­pli­cat­ed billing process­es and pro­to­cols. You can chat with our team dur­ing busi­ness hours via our up­grade page or Read­er Cen­ter should you re­quire spe­cial as­sis­tance. To sign in, you can use a tra­di­tion­al pass­word or click a se­cure “mag­ic link” that we send to your email on file with us. You can al­so send an email to help@end­pointsnews.com.

We re­quire a cred­it card pay­ment but in lim­it­ed cir­cum­stances can in­voice your com­pa­ny if there is no al­ter­na­tive.

To be­gin your com­pa­ny’s paid sub­scrip­tion, click on the but­ton be­low.

Get End­points En­ter­prise

Once again, this is a cru­cial month for this com­pa­ny. You can di­rect­ly sup­port our fu­ture de­vel­op­ment, so we can build on the track we’ve laid so far. We’ll have more posts over the month on our pro­grams but we need your sup­port to­day. Thanks for be­ing part of the End­points News com­mu­ni­ty.

5AM Ven­tures: Fu­el­ing the Next Gen­er­a­tion of In­no­va­tors

By RBC Capital Markets
With Andy Schwab, Co-Founder and Managing Partner at 5AM Ventures

Key Points

Prescription Digital Therapeutics, cell therapy technologies, and in silico medicines will be a vital part of future treatment modalities.
Unlocking the potential of the microbiome could be the missing link to better disease diagnosis.
Growing links between academia, industry, and venture capital are spinning out more innovative biotech companies.
Biotech is now seen by investors as a growth space as well as a safe haven, fuelling the recent IPO boom.

Hal Barron, GSK via YouTube

What does $29B buy you in Big Phar­ma? In Glax­o­SmithK­line’s case, a whole lot of un­com­fort­able ques­tions about the pipeline

Talk about your bad timing.

A little over a week ago, GSK R&D chief Hal Barron marked his third anniversary at the research helm by taking a turn at the virtual podium during JP Morgan to make the case that he and his team had built a valuable late-stage pipeline capable of churning out more than 10 blockbusters in the next 5 years.

And then, just days later, one of the cancer drugs he bet big on as a top prospect — bintrafusp, partnered with Merck KGaA — failed its first pivotal test in non-small cell lung cancer.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

An Endpoints Zoom meeting; and the email header employees will see if your company is a Premium subscriber

What’s next for End­points — and how to sup­port our in­de­pen­dent bio­phar­ma news mis­sion

The firehose of biopharma news is gushing these days.

That’s why broader and deeper is the theme for 2021 at Endpoints. You can expect new coverage outside our core R&D focus, with deeper reporting in some key areas. When John Carroll and I launched Endpoints nearly five years ago, we were wading in waist-high waters. Now we’re a team of 25 full-time staffers (and growing) with plans to cover the flood of biopharma news, Endpoints-style.

Eli Lil­ly's an­ti­body cuts risk of Covid-19 by up to 80% among the most vul­ner­a­ble — but will it have a place next to vac­cines?

Eli Lilly says bamlanivimab lowered the risk of contracting symptomatic Covid-19 in a first-of-its-kind trial involving nursing home residents and staff, paving the way for a new option to protect against the virus.

But how big of an impact it might have, and what role it will play, at a time vaccines are being rolled out to the exact population it is targeting still remains unclear.

Among 965 participants in the study — all of whom tested negative for the coronavirus at baseline — the number of symptomatic cases reported in the bamlanivimab arm was 57% lower than that in the placebo arm (odds ratio 0.43, p=0.00021). In addition to that primary endpoint, all secondary endpoints reached statistical significance.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,400+ biopharma pros reading Endpoints daily — and it's free.

Janet Woodcock (AP Images)

End­points poll: Janet Wood­cock takes the (in­ter­im) helm at the FDA. And a large ma­jor­i­ty of our read­ers want her to stay there

It’s official: Janet Woodcock is now the acting chief of the FDA.

And — according to an Endpoints poll — most industry readers would like her to stay there, although a significant minority is strongly opposed.

To recap: Joe Biden is reportedly choosing between Woodcock and former deputy FDA commissioner Joshua Sharfstein as his nominee for the permanent position. Given their respective track records, the decision is set to determine the agency’s lodestar for years to come.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,400+ biopharma pros reading Endpoints daily — and it's free.

Charlie Fuchs, Roche and Genentech global head of product development for oncology and hematology (Yale Cancer Center)

Yale can­cer spe­cial­ist Char­lie Fuchs tapped as new glob­al de­vel­op­ment chief for Roche/Genen­tech

Roche and their big sub Genentech have just recruited a top cancer specialist at Yale to head up global product development in oncology and hematology.

I just got word that the pharma giant, which leads one of the most active cancer research operations in the world, recruited Charlie Fuchs, director of the Yale Cancer Center and physician-in-chief of Smilow Cancer Hospital. He’ll join the global operation March 1 and will be based in South San Francisco, where Genentech is based.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,400+ biopharma pros reading Endpoints daily — and it's free.

Jonathan Weissman (MIT)

Can a new CRISPR tech­nique un­lock the se­crets of how can­cer spreads?

Jonathan Weissman’s team watched the cancer cells spread across the doomed mouse. Engineered with a bioluminescent enzyme, they appeared in scans first as a small navy blue diamond lodged near the heart; a week later, as a triangle splayed across the mouse’s upper body, with streaks of green and two distinct bright red hubs of activity. By day 54, the mouse resembled a lava lamp.

The images would have been familiar to any cancer biologist, but they didn’t actually tell you much about what was going on: why the cancer was metastasizing or which cells were responsible. For that, Weissman’s team had designed a new tool. Inside the original navy blue diamond, they had engineered the microbiological equivalent of an airplane’s black box — a “molecular recorder” that, after the mouse’s death, could allow them to extract the cells and wind back intimate footage of a single cancer’s ascent.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,400+ biopharma pros reading Endpoints daily — and it's free.

Janet Woodcock and Joshua Sharfstein (AP, Images)

Poll: Should Joshua Sharf­stein or Janet Wood­cock lead the FDA from here?

It’s time for a new FDA commissioner to come on board, a rite of passage for Joe Biden’s administration that should help seal the new president’s rep on seeking out the experts to lead the government over the next 4 years.

As of now, the competition for the top job appears to have narrowed down to 2 people: The longtime CDER chief Janet Woodcock and Joshua Sharfstein, the former principal deputy at the FDA under Peggy Hamburg. Both were appointed by Barack Obama.

Neu­vo­gen un­cloaks with broad plan of at­tack for whole-cell can­cer vac­cines, clin­i­cal hopes with­in the year

After about four stealthy years in the development phase, San Diego-based Neuvogen is emerging with a new approach to whole-cell cancer vaccines and nine solid tumor programs bound for the clinic.

Whole-cell tumor vaccines are developed by taking cancer cells from patients and modifying them to make them immunogenic.

“What’s different from what we do, is most people use one cell line. We use six,” CEO Todd Binder said. From there, the company builds out six modifications to eliminate problematic immunosuppressive factors, and add what the executive called three “stimulatory factors” to generate a prime and overcome peripheral tolerance.